STAT News

STAT+: Lilly’s Jaypirca approved as first-line CLL therapy

Eli Lilly’s Jaypirca has won FDA approval for previously untreated chronic lymphocytic leukemia and small lymphocytic lymphoma.

By STAT News

1 min read
STAT+: Lilly’s Jaypirca approved as first-line CLL therapy
STAT+: Lilly’s Jaypirca approved as first-line CLL therapy

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights